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Tourette syndrome is a neurodevelopmental condition
which affects approximately 0.6% to 1% of 5- to 18-year-
olds.1 The condition is characterized by the occurrence of
tics, which are stereotyped movements and/or vocaliza-
tions. Having Tourette syndrome can have a substantial
negative impact on an individual’s quality of life; conse-
quently, many people with the condition seek treatment to
help manage their tics. Pharmacological and behavioural
interventions can be effective. However, individual out-
comes are highly varied and issues relating to access, avail-
ability, and side effects can be barriers to treatment. There
has been increased interest in the therapeutic application
of non-invasive brain stimulation approaches, including
interventions using repetitive transcranial magnetic stimu-
lation (rTMS).
rTMS has been shown to modulate neural plasticity for
a period of time extending beyond stimulation.2 These
after-effects have been hypothesized to be reliant on synap-
tic events similar to those involved in long-term potentia-
tion and depression, but the exact mechanisms are not yet
understood.2 The capability for rTMS to modulate plastic-
ity has resulted in many studies exploring the therapeutic
potential of this approach for a range of conditions. These
studies typically involve delivering rTMS pulses to a tar-
geted cortical region across a number of sessions, with the
aim of modulating synaptic plasticity and consequently
reducing symptoms.
Studies exploring the use of rTMS as a treatment for
Tourette syndrome have typically targeted the primary
motor cortex (M1) or supplementary motor area (SMA).
This is because dysregulation between the balance of exci-
tation and inhibition within the motor system has been
identified as a core feature of Tourette syndrome, and sev-
eral lines of evidence have implicated alterations within
these cortical regions.3 The most recent example of such
work comes from Kahl et al.4 in which 10 children/adoles-
cents diagnosed with Tourette syndrome received bilateral
stimulation of the SMA over 15 sessions. Tics significantly
reduced for all participants over the course of the study, a
finding that corroborates reports from several small-scale,
open-label trials.5 The authors also endeavoured to mea-
sure physiological change using single/paired-pulse TMS
and magnetic resonance spectroscopy. This approach has
the potential to reveal important biomarkers of change;
however, in this instance few statistically significant differ-
ences were found, likely owing to the small sample size.
Small-scale, open-label studies provide valuable contri-
butions to the investigation of the therapeutic use of
rTMS, though the lack of a sham control is an important
limitation to consider. To date, two small-scale, sham-con-
trolled studies have been published using the SMA as a
stimulation site, both of which revealed strong placebo
effects.5 Yet, numerous methodological differences between
this work and existing open-label studies limits the
strength of conclusions which can be drawn.
The results of studies such as Kahl et al.4 are encourag-
ing. But to truly assess the therapeutic potential of rTMS
it is essential that large-scale, randomized controlled trials
are conducted. Sample sizes should be large enough to
yield sufficient statistical power to assess differences
between sham and active groups, and to assess factors such
as medication use, symptom severity, and the presence of
any comorbid conditions—all of which may contribute
variability to the outcome. Future work should also
endeavour to include measures of physiological change and
include sustained follow-up periods to assess the duration
of any effects. By conducting this type of work, it is possi-
ble that rTMS could become a viable alternative treatment
for people with Tourette syndrome, an outcome which
would be welcome by patients and clinicians alike.
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